Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients

Abstract

The development of COVID-19 syndrome in anticoagulated patients, and especially their admission to intensive-care units with acute severe respiratory syndrome (SARS-CoV-2), expose them to specific problems related to their therapy, in addition to those associated with the acute viral infection. Patients on VKA hospitalized with SARS-CoV-2 show high instability of PT INR due to the variability of vitamin K metabolism, diet, fasting, co-medications, liver impairment, and heart failure. Patients on DOAC are exposed to under/over treatment caused by significant pharmacological interferences. In consideration of the pharmacological characteristics of oral anticoagulant drugs, the multiple pharmacological interactions due to the treatment of acute disease and the possible necessity of mechanical ventilation with hospitalization in intensive-care units, we suggest replacing oral anticoagulant therapies (VKA and DOAC) with parenteral heparin to avoid the risk of over/under treatment.Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Clinical management of a Nigerian patient affected by sickle cell disease with rare blood group and persistent SARS‐CoV‐2 positivity

“…The pulmonary consolidation was interpreted as a consequence of SARS‐CoV‐2 infection and subcutaneous heparin at therapeutic dose (4000 UI/sQ b.i.d.) was initiated [2], along with IV ceftriaxone therapy (2 g). Urine legionella and pneumococcal antigen tests resulted negative.…”

The Multiple Faces of Heparin: Opportunities in COVID-19 Infection and Beyond

“…28 Before recovered patients are discharged from hospital, therapy should be switched from heparin/LMWH to VKA or DOACs after the anticoagulant effects of treatment have been specifically tested. 29…”

Inflammation and thrombosis in patients with COVID-19: a prothrombotic and inflammatory disease caused by SARS Coronavirus-2

“…On the other hand, there are several patients on warfarin or direct oral anticoagulants (DOACs) admitted to the hospitals with COVID-19. During the therapy, severe drug interactions were reported between the different antivirals, anticoagulants, and other therapeutics used in these patients ( 52 ). High instability of PT and INR are common among treated COVID-19 patients, probably due to the variability of vitamin K metabolism, liver involvement, diet, co-medications, and heart failure ( 52 , 53 ).…”